1. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Issue 8 (August 2022) Authors: Munro, Alasdair P S; Feng, Shuo; Janani, Leila; Cornelius, Victoria; Aley, Parvinder K; Babbage, Gavin; Baxter, David; Bula, Marcin; Cathie, Katrina; Chatterjee, Krishna; Dodd, Kate; Enever, Yvanne; Qureshi, Ehsaan; Goodman, Anna L; Green, Christopher A; Harndahl, Linda; Haughney, John; Hicks, Al... Journal: Lancet infectious diseases Issue: Volume 22:Issue 8(2022) Page Start: 1131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗